Nautilus and Abcam Announce Strategic Partnership to Accelerate Exploration of the Proteome
PR92786
SEATTLE and CAMBRIDGE, England, Nov. 2, 2021 /PRNewswire=KYODO JBN/ --
As an element of Nautilus' overall reagent development and sourcing strategy,
the partnership aims to accelerate research and development, and provide
customers with access to Abcam's antibody development technology and expertise
Nautilus Biotechnology, Inc. [ https://www.nautilus.bio/ ](NASDAQ: NAUT; or
"Nautilus"), a company pioneering a single-molecule protein analysis platform
for quantifying the proteome, and Abcam (AIM:ABC; NASDAQ:ABCM), a global
innovator in life sciences research tools, today announced a strategic
development and supply partnership.
The relationship leverages Abcam's industry-leading recombinant monoclonal
antibody development technologies and expertise to enhance Nautilus' reagent
research and development, and establishes a long-term supply relationship
between the companies. The partnership will initially focus on the
collaborative development of affinity binding reagents for use on the Nautilus
proteomic analysis system, and will expand in the near future to the
large-scale manufacture and supply of reagents for commercialization.
"We are excited to be working closely with Abcam to build reagents that we
believe will further enhance our proteomic analysis methods," said Sujal Patel,
co-founder and CEO of Nautilus Biotechnology. "They, like us, envision a future
in which proteomic data is expected to become an increasingly important
resource that has the potential to support the creation of more effective drugs
and diagnostics. Our ability to partner with a company as respected and
successful as Abcam provides a strong vote of confidence in that future, and in
the promise of the Nautilus protein analysis platform to help make it a
reality."
Abcam's scale and recombinant antibody manufacturing expertise is expected to
support Nautilus in meeting its long-term reagent supply needs from research
and development through to commercialization.
"The prospect of biomedical researchers being able to interrogate the proteome
at a more comprehensive level offers exciting possibilities for discovery and
innovation across multiple disease areas," said Alan Hirzel, CEO of Abcam. "By
combining Nautilus' protein analysis platform and Abcam's antibody discovery,
development and manufacturing expertise, we hope to better support scientists
in the development of drugs and diagnostic tools that ultimately improve
outcomes for patients."
Under the terms of the agreement, Abcam will provide Nautilus with antibodies
that are expected to add to and enhance its own library of affinity binding
reagents, highlighting the open and customizable nature of Nautilus'
technology. With simple labeling chemistry, the Nautilus platform is designed
for use with virtually any biological reagent.
About Nautilus Biotechnology, Inc.
Based in Seattle, Washington, Nautilus (Nasdaq: NAUT) is a development stage
life sciences company creating a platform technology for quantifying and
unlocking the complexity of the proteome. Nautilus' mission is to transform the
field of proteomics by democratizing access to the proteome and enabling
fundamental advancements across human health and medicine. To learn more about
Nautilus, visit www.nautilus.bio
About Abcam plc
As a global life sciences company, Abcam identifies, develops, and distributes
high-quality biological reagents and tools that are crucial to research, drug
discovery and diagnostics. Working across the industry, the Company supports
life scientists to achieve their mission, faster.
Abcam partners with life sciences organizations to co-create novel binders for
use in drug discovery, in vitro diagnostics and therapeutics, driven by the
Company's proprietary discovery platforms and world-leading antibody expertise.
By constantly innovating its binders and assays, Abcam is helping advance the
global understanding of biology and causes of disease, which enables new
treatments and improved health. The Company's pioneering data-sharing approach
gives scientists increased confidence in their results by providing validation,
user comments and peer-reviewed citations for its 90,000 products.
With 14 sites globally, many of Abcam's over 1,600-strong team are located in
the world's leading life sciences research hubs, complementing a global network
of service and support.
To find out more, please visit www.abcam.com and corporate.abcam.com.[
https://corporate.abcam.com/ ]
Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of
federal securities laws. You can identify forward-looking statements by words
such as "may," "will," "could," "can," "would," "should," "expect," "intend,"
"plan," "anticipate," "believe," "estimate," "predict," "project," "potential,"
"poised," "continue," "ongoing" or the negative of these terms or other
comparable terminology, but not all forward-looking statements will contain
these words. Forward-looking statements in this press release include, but are
not limited to, statements regarding the potential functionality and
performance of Nautilus' product platform, its potential impact on
pharmaceutical development and drug discovery, and market opportunities
available to Nautilus or Abcam generally. These statements are based on
numerous assumptions concerning the collaboration between Abcam and Nautilus
including but not limited to expectations as to the success of that
collaboration, expectations regarding the ability of that collaboration to
enhance and/or accelerate Nautilus' development efforts and to enable Nautilus
to meet long term reagent supply needs, and expectations regarding the
development of Nautilus' products and target markets, generally, and involve
substantial risks, uncertainties and other factors that may cause actual
results, levels of activity, performance or achievement to be materially
different from the information expressed or implied by these forward-looking
statements. We cannot assure you that the forward-looking statements in this
press release or the assumptions upon which they are based will prove to be
accurate. Risks and uncertainties that could materially affect the accuracy and
outcome of Nautilus' and Abcam's assumptions and its ability to achieve the
forward-looking statements set forth in this press release include (without
limitation) the following: Nautilus' product platform is not yet commercially
available and remains subject to significant scientific and technical
development, which is inherently challenging and difficult to predict,
particularly with respect to highly novel and complex products such as those
being developed by Nautilus. Even if Nautilus' development efforts are
successful, the product platform will require substantial validation of its
functionality and utility in life science research. In the course of Nautilus'
scientific and technical development and associated product validation and
commercialization, Nautilus or Abcam may experience material delays as a result
of unanticipated events. For a more detailed description of additional risks
and uncertainties facing Nautilus and its development efforts, investors should
refer to the Registration Statement on Form S-4 and related documents filed
with the SEC. For a more detailed description of additional risks and
uncertainties facing Abcam and its development and business strategy see the
important factors discussed under the caption "Risk Factors" in Abcam's
prospectus pursuant to Rule 424(b) filed with the U.S. Securities and Exchange
Commission ("SEC") on 22 October 2020, which is on file with the SEC and is
available on the SEC website at www.sec.gov, as such factors may be updated
from time to time in Abcam's other filings with the SEC. The forward-looking
statements in this press release are as of the date of this press release.
Except as otherwise required by applicable law, Nautilus and Abcam disclaim any
duty to update any forward-looking statements. You should, therefore, not rely
on these forward-looking statements as representing our views as of any date
subsequent to the date of this press release.
Logo - https://mma.prnewswire.com/media/1675313/Nautilus_Abcam_logo.jpg
Joint Source: Abcam and Nautilus Biotechnology, Inc.
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。